Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target.

1. Introduction

Cells need appropriate oxygen (O 2 ) concentration to allow aerobic respiration, and in turn, to produce ATP, the energetic fuel used in a large number of biological processes. Pathological (cancer, inflammation, diabetes) and non-pathological phenomena (high altitude) may induce hypoxia condition. Hypoxia is a hallmark of tumor microenvironment present in the majority of solid tumors [ 1 ] as a consequence of an imbalance between increased oxygen consumption and inadequate oxygen supply due to a rapid cellular proliferation that outgrows the surrounding vasculature [ 2 ]. Cancer cells adapt to hypoxia by altering their metabolism through a gene expression reprogramming and proteomic changes that impact various cellular and physiological functions, including energy metabolism, vascularization, invasion and metastasis, genetic instability, cell immortalization, stem cell maintenance, and resistance to chemotherapy [ 3 ]. Under hypoxic conditions, cell proliferation is reduced to prevent further increase of O 2 -consuming cells. However, cancer cell mutations and genetic alterations in oncogenes or tumor-suppressor genes together with a highly dynamic metabolic reprogramming allow cell proliferation, despite low-oxygen concentration [ 4 ]. Moreover, metabolic rewiring enhances epithelial–mesenchymal transition, invasiveness, and metastatic properties of cancer cells [ 5 ].

The metabolic reprogramming, likely through inflammatory mechanisms, also affects distant non-tumor tissues such as adipose tissue and liver and skeletal muscles, inducing an overall energetic dysregulation [ 6 ]. This severe state, also called cancer cachexia, leads patients to loss of adipose and muscle mass, weakening, and anorexia, drastically reducing both the quality of life and the effectiveness of anti-cancer treatments [ 7 ]. At present, biomarkers addressed to antimetabolic treatments and clarification of the interplay between metabolic rewiring, including hypoxic adaptation, and epithelial–mesenchymal transition are topical fields of investigation [ 8 ]. Prevention of metabolic rewiring and resultant adverse events of cancer cells may represent an important approach for the treatment of metastatic cancers.

Among the cellular components, mitochondria are the major consumers of oxygen since they drive cellular bioenergetics, therefore they are severely damaged by decreased oxygen availability. In response to hypoxia, mitochondria adjust their metabolism in different ways, including exchanging or modifying subunits of the respiratory chain, decreasing oxidative phosphorylation (OXPHOS), lowering the tricarboxylic acid (TCA) cycle intermediates, adapting reactive oxygen species (ROS) production, and reducing β-oxidation [ 9 ]. Another adaptive response of mitochondria to hypoxic condition involves a reduction of their mass by an autophagy mechanism and inhibition of their biogenesis [ 10 ]. Moreover, mitochondrial TCA cycle intermediates participate in modulating the hypoxia-inducible factors (HIF), the key regulators of adaption to hypoxia.

The transcriptional factor HIF-1 orchestrates the cellular adaptive mechanisms triggered in response to a low-oxygen environment. In fact, most oxygen-regulated genes contain specific responsive elements (hypoxia response elements, HREs) that bind to HIF, leading to an adaptive response to hypoxia and tumor progression and metastasis. Therefore, significant efforts have been made in the last two decades towards understanding the role of HIF family members, in particular HIF-1α, in the adaptive response of cell to hypoxia and in the crosstalk between HIF-1 and mitochondria. This review will focus on the role of HIF-1 in the metabolic reprogramming and in the functional adaption of mitochondria to hypoxia in cancer cells.

2. HIF-1α Structure

Three members of the HIF family have been identified. They all consist in a heterodimeric structure composed by an O 2 -sensitive α subunit (HIF-1α, HIF-2α, and HIF-3α) and an O 2 -insensitive β subunit (HIF-1β), also known as aryl hydrocarbon receptor nuclear translocator (ARNT) [ 11 ]. Among them, HIF-1α is the most well-characterized isoform thanks to the structural and functional studies performed on mammals. HIF-1α consists of 826 amino acids and HIF-1β of 789 amino acids. Both subunits belong to the basic helix-loop-helix/Per-ARNT-Sim (bHLH-PAS) family of transcription factors. Two regions of amino sequences (PAS-A and PAS-B) and HLH domain, located in the first half of subunits, are responsible for heterodimerization between HIF-1α and HIF-1β ( Figure 1 ). The basic regions upstream of the N-terminal of the HLH domain of both HIF-1α and HIF-1β subunits mediate the binding to the HRE of target gene promoters ( Figure 1 ) [ 12 ]. Differences in terms of structure and function are present in the second half of subunits. Two transactivation domains (TADs), N-TAD (N-terminal TAD) and C-TAD (C-terminal TAD), are present in HIF-1α subunit. Both domains are rich in acidic and hydrophobic amino acids. They are separated by a region known as the inhibitory domain (ID) ( Figure 1 ), responsible for suppression of transcriptional activity under normoxic conditions [ 13 ]. The C-TAD regulates transactivation of target genes ( Figure 1 ) through the recruitment of coactivators CBP and p300 in both subunits [ 14 ]. Upstream of the N-TAD region, HIF-1α contains the oxygen-dependent degradation (ODD) domain that mediates the hydroxylation of two proline residues and the acetylation of a lysine, followed by proteasomal degradation ( Figure 1 ). HIF-1β subunit lacks the ODD and the N-TAD domains but contains C-TAD alone ( Figure 1 ). This structural difference reflects the function of subunits.

In fact, HIF-1α is responsible for transcriptional activity since it contains the transactivation domains, whereas HIF-1β is only the dimerization partner and is not needed for the induction [ 15 ]. The oxygen cellular tension regulates the stability and functionality of HIF-1α. While HIF-1β is constitutively stable and active under both aerobic and hypoxic conditions, HIF-1α subunit is rapidly degraded in normoxic conditions by the ubiquitin-proteasome system [ 16 ]. Indeed, detection of protein expression in different human tissues can evidence low levels of HIF-1α protein in normoxic cells (due to proteasomal degradation), even when HIF-1α is overexpressed, but a high induction in hypoxic cells. Conversely, HIF-1β levels were stable, regardless of pO 2 [ 17 ].

The second member of the HIF family, HIF-2α shares some structural similarities with HIF-1α but has a different pattern of expression and functional properties. Like HIF-1α it shows the same ability to heterodimerize with HIF-1β [ 18 ]. Unlike HIF-1α, which is ubiquitous, HIF-2α shows an abundant expression in embryonic cells and adult vascular endothelial cells, lungs, placenta, and heart [ 19 , 20 , 21 ]. Differences have also been found in their transcriptional targets. As reported in the next sections, HIF-1α is involved in different metabolic pathways, while HIF-2α is more effective on erythropoietin (EPO) gene and on Fe metabolism. Both regulate other genes such as VEGF and GLUT-1 [ 22 , 23 ]. Interestingly, primary renal cell carcinoma revealed a correlation between HIF-2α (but not HIF-1α) and generation of lipid droplets (see Section 3.3 ).

The third member, HIF-3α, shows 57% and 53% amino acids sequence identity in the bHLH-PAS domain with HIF-1α and HIF-1β respectively, and 61% identity in the ODD domain with HIF-1α [ 24 ]. It contains N-TAD domain, but lacks the C-TAD domain ( Figure 1 ). Of note, a leucine zipper (LZIP) domain, which is responsible for interaction between proteins, was found in a HIF-3α variant [ 25 , 26 ]. Additionally, this member can heterodimerize with HIF-1β. Experimental evidence shows that, under hypoxia, it is expressed in adult mice thymus, lung, brain, heart, and kidney [ 27 ]. Multiple HIF-3α splice variants have been found, but their specific functional activity is still unknown. Interestingly, they all are induced by hypoxia via the involvement of HIF-1α, but not HIF-2α [ 28 ].

The mechanism by which HIF-1α is degraded in normoxia involves the post-transcriptional hydroxylation of P402 and P564 within the ODD domain by prolyl hydroxylase domain protein 2 (PHD2). The enzyme requires molecular oxygen, α-ketoglutarate (αKG), and Fe(II) and generates succinate and CO 2 as by-products ( Figure 2 ) [ 29 ]. In the oxygenated form, HIF-1 recognizes the von Hippel-Lindau tumor suppressor protein, which binds ubiquitin-conjugated E2 component to assemble the protein complex for the degradation by the ubiquitin-proteasomal pathway. Another HIF-1α hydroxylation reaction occurs in well-oxygenated cells: the hydroxylase called factor inhibiting HIF-1 (FIH-1), a Fe(II)- and αKG-dependent dioxygenase, hydroxylates N803 with consequent disturbance of the interaction between HIF-1α and transcription coactivators CBP/p300 ( Figure 2 ) [ 14 , 30 ]. Under hypoxic conditions, PHD2 and FIH-1 lose their activity, giving rise to stabilization, nuclear translocation of HIF-1α, and activation of HIF target genes ( Figure 2 ) [ 31 ]. As a consequence of reduced pO 2 , mitochondria increase the production of ROS which oxide Fe(II) present in the active sites of dioxygenases, causing their inactivation [ 32 ]. It is also known that HIF-1α can be stabilized by ROS generated by other mechanisms such as the NADPH oxidase system, in particular the NOX family of oxidase [ 33 ].

3. Metabolic Reprogramming in Hypoxia Induced by HIF-1

Cancer cell metabolism is reprogrammed in hypoxia, thus taking advantage from these adaptions to fuel survival, proliferation, and ensure tumor progression. Glucose metabolism is particularly affected. Recent advances also highlighted the active involvement of HIF-1 in the regulation of the metabolism of two amino acids, glutamine and serine, together with one-carbon cycle and the fatty acid metabolism in hypoxic cancer cells.

3.1. Glucose Metabolism

Cancer cells use more glucose than normal cells. In hypoxia, different genes involved in glycolysis are under HIF-1 transcriptional control, such as glucose transporters (GLUT1 and GLUT3), glycolytic enzymes (i.e., hexokinase 1 and 2, enolase 1, phosphoglycerate kinase 1, pyruvate kinase M2), and lactate dehydrogenase (LDHA) [ 34 , 35 ]. Among them, the pyruvate kinase M2 gene ( PKM2 ) plays different roles since it encodes two isoforms, PKM1 and PKM2, by an alternative splicing mechanism. In cancer cells, expression of PKM2 is induced, promoting cell proliferation [ 36 ]. Once activated, PKM2 triggers different biological pathways as a transcriptional activator for octamer-binding transcription factor 4, HIF-1α, HIF-2α, and β-catenin [ 37 , 38 ]. PKM2 enzyme acts as a coactivator of HIF-1α itself to stimulate chromatin binding, coactivator recruitment, and transcriptional activation [ 39 ], leading to a metabolic reprogramming of cancer cells and favoring other processes of cancer progression, such as angiogenesis. Furthermore, PKM2 can also phosphorylate the transcriptional factor STAT3 [ 40 ]. However, PKM2 mainly acts as pyruvate kinase in glycolysis, although it is differently regulated than its isoform PKM1. In fact, its activity is regulated in an allosteric way by phosphopeptides [ 41 ], metabolites [ 42 ], and other post-translational modifications such as phosphorylation, acetylation, and oxidation [ 43 , 44 , 45 ]. Generation of different glycolytic intermediates can be used for nucleotide and lipid synthesis [ 46 ]. In normoxia, pyruvate is converted to acetyl-CoA by pyruvate dehydrogenase complex (PDH) for entry into TCA cycle. In hypoxia, PDH is inactivated by phosphorylation at its catalytic domain by pyruvate dehydrogenase kinase 1 (PDK-1) induced by HIF-1, giving rise to a reduced delivery of NADH and FADH 2 to electron transport chain (ETC) to generate ATP [ 3 ]. Induction of glycolysis together with inhibition of PDH favors production of lactate, which stabilizes HIF-1, a metabolic process very active in tumor cells characterized by a shift from OXPHOS to anaerobic glycolysis [ 47 ].

In the context of glucose metabolism reprogramming in hypoxia, the pentose phosphate pathway activity also decreases due to a reduced expression of glucose-6-phosphate dehydrogenase. As a consequence, synthesis of nucleotides and cell proliferation are affected. Contextually, phosphoglycerate dehydrogenase is induced, resulting in a diversion of glucose towards serine synthesis, as described later.

Finally, under hypoxia, HIF-1 also stimulates glucose conversion into glycogen, thus ensuring energy storage to survive prolonged stress. Depending on the metabolic demands of specific cancer cells, glycogen metabolism is subjected to a dynamic process of synthesis and degradation in hypoxic conditions of cancer cells. Different enzymes involved in glycogen synthesis are induced, including glycogen synthase 1, glycogen branching enzyme, UDP-phosphorylase, and phosphoglucomutase 1 [ 34 ]. The glycogen phosphorylase enzyme involved in the degradation of glycogen is highly expressed in cancer cells. This enzyme has been tested in pancreatic cancer and U87 glioma as a therapeutic target by its inhibitor C-320626 [ 48 , 49 ]. Taken together, these studies indicate a primary role for HIF-1 in modulating the dynamic glucose metabolism of hypoxic cancer cells.

3.2. Lactate and Acidification

As a result of the hypoxia-related metabolic changes, the lactate concentration ranges from 1.5 to 3 mM in normal cells to 10–30 mM in cancer cells, resulting in intracellular acidification [ 50 , 51 ]. To avoid this effect, an efflux of lactate and H + to the extracellular space occurs through proton-like monocarboxylate transporters (MCTs) [ 52 , 53 ]. Lactate export is also required to support high glycolytic rates, as increased cytosolic lactate levels inhibit phosphofructokinase 1 (PFK1) catalyzing one of the key rate-limiting steps of glycolysis [ 54 ]. Lactate efflux together with high activity of the carbonic anhydrase IX—which reversibly hydrates carbon dioxide to bicarbonate ions and H + —induces an acidification of the extracellular pH (6.0–6.5) in tumor microenvironment [ 55 ]. Acidic extracellular pH represents a hallmark of cancer. These events make the environment unfavorable for cell growth and help tumor progression since cancer cells have developed more adaptation than normal cells to these conditions. Moreover, extracellular lactate-driven acidification promotes immune evasion by inhibiting activation and proliferation of CD4, CD8, NK, NKT, and dendritic cells, and by leading to apoptosis of CD8 lymphocytes and NK cells [ 56 ]. Thus, hypoxia-induced tumor microenvironment acidification lowers antitumor immunity. Lactate itself could be a respiratory substrate in cancer cells [ 57 ]. Lactate and H + are exported outside cells by the monocarboxylate transporter, carbonic anhydrase 9 and Na + /H + exchanger isoform 1 [ 58 ]. Extracellular lactate can be used as an anaplerotic source of substrates for TCA cycle, triggered in cancer cells. In particular, evidence from Faubert et al. shows that lactate is the preferred anaplerotic substrate in human non-small-cell lung cancers since cancer cells incorporate more lactate-derived carbons into TCA cycle than those from glycolysis [ 59 ]. Moreover, excreted lactate contributes to regulate pH homeostasis inside the cell and acidification of the extracellular space. Lactate and/or protons in the microenvironment regulate the function of immune cells and promote invasion and metastasis [ 60 ]. Since T cells also depend on glycolysis, cancer cells and T cells compete for glucose uptake. However, tumor cells take up most of the glucose and thereby create a state of glucose deprivation for T cells, leading to T cell anergy or death [ 61 ].

3.3. Lipid Metabolism

Cancer cells have an increased lipid content [ 62 ]. In hypoxic conditions, HIF-1 induces lipid droplet accumulation and uptake, and reprograms β-oxidation and ex novo biosynthesis of fatty acids. Regarding the uptake, FABP3 and FABP7, the fatty acid binding proteins, and ADRP, the factor required for droplet formation, are induced by HIF-1. This condition protects against ROS and contributes to cell growth and survival after hypoxia regeneration [ 63 ].

HIF-1 suppresses the mitochondrial fatty acid oxidation through inhibition of medium-chain Acyl-CoA dehydrogenase (MCAD) and long-chain Acyl-CoA dehydrogenase (LCAD), resulting in reduction of ROS and suppression of the PTEN pathway, thus promoting tumor cell proliferation [ 64 ]. Inhibition of fatty acid oxidation contributes to maintain redox homeostasis in hypoxia. HIF-1α suppresses the expression of c-Myc, a transcriptional coactivator of PGC-1β, required for MCAD and LCAD. Interestingly, carnitine palmitoyltransferase 1A, the rate-limiting component of mitochondrial fatty acid transport, is repressed by HIF-1 and HIF-2, resulting in reduction of transport into mitochondria and forcing fatty acids to lipid droplets formation [ 65 ].

Lipid biosynthesis becomes critical in high proliferating cancer cells to support organelle membrane production and modulation of their fluidity, to supply triglyceride formation for energy storage, and to produce signaling molecules such as sphingosine 1-phospahte and lysophosphatidic acid involved in the cancer cell migration, inflammation, and survival [ 66 ]. In hypoxia, the precursor of fatty acid biosynthesis, acetyl-CoA, comes from alternative sources than the normal glucose pathway. In addition to glutamine or some amino acids, acetyl-CoA derives from acetate through the cytosolic acetyl-CoA synthetase. Acetyl-CoA not only serves as a substrate for fatty acid biosynthesis, but it also acetylates HIF-2 by its coactivator CBP, leading to increased cancer cell motility and invasion [ 67 ].

HIF-1 also promotes the expression of fatty acid synthase to trigger fatty acid synthesis and stearoyl-CoA desaturase (SCD) to stimulate the unsaturated fatty acid generation [ 35 ]. In hypoxic conditions, the ratio between saturated/unsaturated fatty acids is altered because the oxygen-dependent SCD enzyme is inhibited [ 68 ], thus affecting plasma and organelle membrane integrity and cell function. This imbalance is compensated by the induction of expression of SCD, as observed in some type of tumors, such as prostate, breast, liver, and kidney cancers [ 69 ]. Maintaining the saturated/unsaturated fatty acid ratio is important since induction of saturated fatty acid biosynthesis is harmful if not compensated. In fact, toxicity derived from saturated fatty acid induction is alleviated by exogenous unsaturated fatty acid intake in cancer cells [ 68 ]. Moreover, ATP citrate lyase (ACLY) is upregulated in hypoxic tumor cells and seems to be a target gene of HIF-1α [ 70 ]. Indeed, as an enzyme at the interface between glucose and lipid metabolism, ACLY is essential not only for fatty acid biosynthesis but also for acetyl-CoA production [ 71 ]. ACLY is also a component of the citrate/pyruvate shuttle important for NADH oxidation and NADPH production for lipid metabolism, redox homeostasis, and molecular biosynthesis [ 72 ].

The induced synthesis of fatty acids leads to an increased production of neutral triacylglycerols (TAGs), stored as lipid droplets (LDs) to be used as energy depots. Two main enzymes, AGPAT2 (acylglycerol-3-phosphate acyltransferase 2) and lipin-1 (a phosphatidic acid phosphatase) are induced by HIF-1 mediating LD accumulation [ 73 , 74 ]. Both enzymes are necessary not only for LD accumulation and viability, but in the onset of chemoresistance under hypoxia [ 75 ]. The products of AGPAT2 catalytic activity, lysophosphatidic acid (LPA) and phosphatidic acid (PA), can also be used for new membrane formation [ 76 ]. Hypoxic conditions also induce expression of other constituents of LD membranes. Transcriptional profiling of primary renal cell carcinoma revealed a correlation between HIF-2α (but not HIF-1α) and high expression of the lipid droplets coat protein perilipin 2 (PLIN2). The HIF-2α-dependent PLIN2 expression promoted triglycerides and cholesterol storage in lipid droplets needed for maintaining integrity of the endoplasmic reticulum and its homeostasis, particularly under conditions of nutrient and oxygen limitation, thereby promoting tumor cell survival [ 77 ]. In addition, HIF-1 increases lipid accumulation in both cancer and normal cells by induction of HIG2/HILPDA (hypoxia-inducible protein 2/hypoxia-inducible lipid droplet-associated) [ 78 , 79 ]. As a consequence of HIG2 upregulation, the adipose triglyceride lipase (ATGL) is inhibited, resulting in impairment of intracellular lipolysis in various cancer cells [ 80 ].

Another aspect of lipid metabolism concerns the lipid droplets’ composition. Interestingly, Ackerman et al. found that, in hypoxia, the unsaturated fatty acid oleate is preferentially released from lipid droplets triglycerides into the phospholipids pool to counter the build-up of saturated lipids [ 81 ]. Finally, it should be mentioned that different lipid signaling molecules, such as sphingosine kinase 1, stimulate HIF-1 activity [ 82 ].

3.4. Amino Acids’ Metabolism

Metabolism of two non-essential amino acids, glutamine and serine, is particularly affected by hypoxia in cancer cells. These amino acids are more than a simple substrate for protein synthesis since their metabolism is crucial for proliferating cells.

Glutamine is one of the primary substrates in cancer cells. It can be utilized to supply TCA cycle, to support biosynthesis, energetics, and cellular homeostasis as a source of carbon and nitrogen. The decreased entry of pyruvate into TCA cycle triggers a compensatory anaplerosis consisting in the increase of glutamine uptake through induction of glutamine transporters SLC1A5 and SNAT2/SLC38A2 [ 83 , 84 ]. Inside cells, glutamine is converted into glutamate by glutaminase and then into αKG by glutamate dehydrogenase or transaminase. αKG can be converted into succinate for entry into TCA cycle or subjected to reductive carboxylation by isocitrate dehydrogenase (IDH), giving rise to isocitrate and citrate [ 85 ]. A shift from oxidation to reductive carboxylation occurs in hypoxic conditions by a mechanism involving HIF-1. In hypoxic glioblastoma cells, most of the citrate comes from glutamine through reductive carboxylation. The same cell line is unable to proliferate in citrate starvation or IDH2- silencing [ 86 ].

Oxidation of αKG also depends on HIF-1 in hypoxic cancer cells. In fact, HIF-1 activation promotes SIAH2-targeted ubiquitination and proteolysis of the 48 kDa splice variant of the E1 subunit of the α-ketoglutarate dehydrogenase complex. Under induction of HIF-1, an increase of the glutamine utilization in P493 cells (model of Burkitt lymphoma) has been observed [ 87 ]. Furthermore, in clear cell renal cell carcinoma, the presence of inactivating mutations of the von Hippel-Lindau tumor suppressor gene stabilize HIF proteins, which accumulate to supraphysiologic levels and activate the transcription of genes such as vascular endothelial growth factor and platelet-derived growth factor. All these events contribute substantially to the tumor physiology and have been assessed indirectly as a prognostic factor [ 88 ]. In these cancer cells, glutamine is used to generate aspartate needed for de novo pyrimidine synthesis via reductive carboxylation [ 89 ]. Glutamine-derived glutamate may be utilized for other biological processes, such as glutathione synthesis, transamination reaction, precursor of other amino acids’ biosynthesis, and to drive the tumor growth [ 90 , 91 ].

Serine plays a central role in cancer cells’ growth. In fact, its depletion inhibits the growth of some cancer cells in vitro and in vivo [ 92 ]. It exerts a multifunctional role: the synthesis of other amino acids (glycine and cysteine), production of phospholipids (phosphatidylserine), and donor of one-carbon units in the folate pathway. In hypoxia, serine synthesis from glucose is induced by three enzymes: phosphoglycerate dehydrogenase (PHGDH), phosphoserine amino transferase, and phosphoserine phosphatase. PHGDH is overexpressed in some types of cancer, such as non-small cell lung, cervical, colorectal, and breast cancers [ 93 , 94 , 95 ]. However, Samanta et al. showed that some breast cancer cell lines have no PHGDH overexpression, which can be amplified only in an HIF-dependent manner under hypoxic conditions [ 96 ]. Furthermore, HIF-1 activates the transcription of SLC7A11, encoding the cysteine transporter, and GCLM, encoding the regulatory subunit of the glutamate-cysteine ligase, to increase glutathione synthesis.

One-carbon cycle is strictly related to the serine metabolism [ 97 ]. It is involved in the NADPH generation and redox regulation. Specifically, NADPH is necessary for the conversion of glutathione from oxidized (GSSG) to reduced (GSH) form and to protect against increased mitochondrial ROS generated by ETC [ 98 ]. In hypoxia, breast cancer cells produce NADPH to maintain the reduced form of glutathione and support the cell survival. PHGDH knockout reduces production of NADPH and increases ROS amount, resulting in increase of apoptosis [ 99 ]. Three mitochondrial enzymes of the folate cycle, hydoxymethyltrasferase 2 (SHMT2), methylene tetrahydrofolate dehydrogenase, and methylene tetrahydrofolate dehydrogenase 1-like, are induced by HIF-1 in hypoxic conditions. Mitochondrial degradation of serine to CO 2 and NH 4 + by SHMT2 increases a net production of NADPH favoring antioxidant defenses in hypoxic cells. In fact, knockdown of SHMT2 in MYC-dependent cells or in vivo suppression of SHMT2, in addition to reduction of cellular NADPH, increases ROS production, triggers hypoxia-induced cell death, and impairs tumor growth [ 100 ].

4. Impact of Hypoxia on Mitochondrial Function

Mitochondria play a critical role in cancer cells. Thus, in hypoxic conditions, cancer cells rewire important mitochondrial functions and biogenesis. Different mitochondrial processes, such as oxidative phosphorylation, TCA cycle, ROS generation, as well as mitochondrial dynamics (i.e., mitophagy), are significantly affected by decreased oxygen availability. In this section, we summarize mitochondrial metabolic and molecular changes and the role of HIF-1 as a master regulator of mitochondrial redox homeostasis by decreasing oxidant production and increasing antioxidant capacity in hypoxia

4.1. TCA Cycle

It is known that TCA cycle plays a dual role as a producer of NADH and FADH 2 , which fuel the mitochondrial electron transport chain to generate ATP, and as a supplier of metabolic intermediates required for anabolic reactions. Highly proliferating cancer cells require a continuous supply of precursors for the synthesis of lipids, proteins, and nucleic acids in hypoxic conditions in which a reprogramming of TCA cycle is triggered. Inactivation of PDH at its catalytic site by the PDK-1 phosphorylation significantly reduces the conversion of pyruvate to acetyl-CoA, thus reducing the TCA cycle flux, which limits the availability of reducing equivalents for the ETC. Under hypoxic conditions, reduction of TCA cycle activity lowers the levels of aspartate that is generated form the TCA cycle metabolite oxaloacetate. Aspartate is needed for nucleotide synthesis and cell proliferation; thus, its reduction impairs cell proliferation in vitro and cancer cells’ growth in a mouse model [ 101 , 102 ]. Mutations in the TCA cycle components, such as succinate dehydrogenase (SDH), fumarate hydratase, and isocitrate dehydrogenase (IDH1 and IDH2), lead to accumulation of succinate, fumarate, and L-2-hydroxyglutarate (L-2HG), respectively [ 103 ]. These metabolites decrease the activity of PHDs ( Figure 3 ), resulting in a stabilization of HIF-1α subunit, which accelerates multiple steps of metastasis [ 104 ]. On the contrary, another TCA cycle intermediate, αKG, acts as a co-substrate of PHD. However, αKG accumulation promotes the production of L-2HG oncometabolite via LDHA and malate dehydrogenase activity in the cytosol (MDH1), and in the mitochondria (MDH2) [ 105 ]. The L-2HG enantiomeric form in turn inhibits PHDs. Therefore, dysregulations of TCA cycle enzymes and/or metabolites regulate PHD function, and consequently HIF-1α stability. These studies concerning the dysregulation of TCA represent a molecular strategy by which hypoxic cells decrease oxidative metabolism.

4.2. Electron Transport Chain

The electron transport chain contains different redox centers that transport electrons to oxygen, producing two molecules of water. Complex IV, the last component of the electron transport chain, shows a high affinity for oxygen (K m close to 0.1% O 2 ) to ensure production of ATP, also during hypoxia. However, prolonged hypoxic state may lead to a reduction of ETC function. Unexpectedly, reduction of ATP activity does not depend on the oxygen deficiency, but it is mainly based on a HIF-1-dependent mechanism. Complex IV, also known as cytochrome oxidase (COX), consists in 13 subunits (10 nuclear DNA-encoded and 3 mitochondrial DNA-encoded). In hypoxia, HIF-1 induces the expression of the nuclear-encoded subunit COX4I2 and the mitochondrial LON protease. COX4I2 replaces COX4I1 in complex IV assembly and then COX4I1 is targeted by LON for proteasomal degradation [ 3 ]. Incorporation of COX4I2 improves the complex activity in transferring electrons to oxygen in hypoxic condition, resulting in reduction of ROS production, maintenance of ATP production, and preserving the integrity of Complex IV ( Figure 3 ). Efficiency of Complex IV is ensured by the action of HIF-1, a positive regulator of COX, which causes structural changes around heme a , the active center driving the proton pump [ 106 ].

HIF-1 increases expression of the mitochondrial NDUFA4L2 encoding NADH dehydrogenase (ubiquinone) 1/subcomplex subunit 4-like 2, which suppresses Complex I activity [ 107 ]. Reducing the mitochondrial Complex I activity via NDUFA4L2 is an essential process in the mitochondrial reprogramming induced by HIF-1 that leads to a reduction of intracellular ROS production and preservation of membrane potential ( Figure 3 ). Interestingly, NDUFA4L2 knockdown suppresses tumor growth and metastasis in vivo [ 108 ].

miRNA-210 (miR-210) is another established target of HIF-1 in the adaption of respiration in hypoxic conditions aimed to decrease oxidative metabolism. This small RNA inhibits expression of iron–sulfur cluster assembly proteins (ISCU1 and ISCU2) required for Complex I assembly [ 109 ]. Decrease of ISCU induces ROS formation under hypoxia [ 110 ]. Although NDUFA4L2 and ISCU1/2 are both HIF-1-regulated proteins, they play an opposite role in the production of ROS in hypoxia. While NDUFA4L2 induction increases ROS, reduction of ISCU decreases ROS production. Furthermore, hypoxia also affects the Complex I conformation change from an active (ROS-producing) to silent (ROS not producing) form, resulting in a decrease of ROS. Although the mechanism is not fully understood [ 111 ], it is likely that subunits, such as NDUFA9, ND1, and ND3, are involved in this process [ 112 ]. Furthermore, HIF-1-induced miR-210 also targets succinate dehydrogenase, a membrane-bound and heme b -containing subunit of Complex II of the ETC. Expression of SDH decreases in A549 cells transfected with miR-210, resulting in a lower activity of Complex II [ 113 ]. In addition to Complex I and II, Complex IV subunits, COX10 and NDUFA4, have been identified as miR-210 targets [ 114 , 115 ]. Therefore, HIF-1 may regulate ETC directly or through miR-210 in hypoxic cancer cells. These data concerning the replacement of distinct proteins, altering the function of the complexes of ETC, can be considered a fast and flexible system to adapt to hypoxic conditions without building an entire new complex.

4.3. Mitochondrial Biogenesis and Autophagy

HIF-1 activates BCL2 interacting protein 3 (BNIP3) and BNIP3-like (BNIP3L), two mitochondria-associated proteins belonging to the BCL2 family, which trigger mitochondrial selective autophagy ( Figure 3 ). Mitophagy [ 116 ] is an adaptive mechanism to face the reduced oxidative metabolism in order to maintain oxygen homeostasis and contribute to metabolic reprogramming in hypoxic conditions of cancer cells [ 117 , 118 ]. In different cancers, autophagy is also repressed through glutamine by suppressing GCN2 (amino acid-sensing kinase) and stimulating mTOR [ 119 ]. In addition to induction of autophagy, HIF also suppresses mitochondrial biogenesis by transactivation of MXI1, a transcriptional repressor that negatively regulates MYC function. All together, these mechanisms play a protective role by decreasing ROS production in mitochondria. Thus, they can be considered as part of a general mechanism of cell survival that is controlled by HIF-1.

4.4. ROS

Though ROS can be produced by NADPH oxidase and non-enzymatic mechanisms, mitochondria are the powerful source of ROS (mtROS) by ETC, especially superoxide anion (O 2 •− ) produced at the level of Complex I and Complex III, and ROS-detoxifying enzymes. Hypoxia leads to mtROS production, alerting cells to a shortage of oxygen. In turn, mtROS activate HIF transcription factors and induce the expression of HIF target genes, including those involved in metabolism and angiogenesis ( Figure 3 ). A steady-state level of ROS is needed in cancer cells to allow cell proliferation and HIF activation. This redox balance is also aimed to avoid accumulation of ROS that would incur cell death or senescence. Thus, mtROS levels are tightly regulated in cancer cells. Serine catabolism through one-carbon metabolism maintains this mitochondrial redox balance during hypoxia [ 100 ]. Interestingly, cancer cells can protect mitochondria under hypoxia by an increased expression of antioxidant proteins [ 120 ]. Thus, cytoplasmatic and intermembrane space superoxide dismutase 1 (SOD1) and mitochondrial matrix SOD2 are upregulated in hypoxic conditions, enhancing superoxide detoxification and producing H 2 O 2 . These findings highlight that mitochondrial-derived ROS can be considered not only harmful substances but important signaling molecules, and their level has to be strictly controlled to avoid cell death.

5. Targeting HIF-1 in Cancer Therapy

Since the HIF system and related hypoxia are crucial events in cancer cells, they have been proposed as possible therapeutic targets in cancers. In recent years, different strategies and drugs have been tested and proposed as therapeutic tools to impair the HIF activity and related pathways, but only few of them are in clinical trials due to tolerance limitations, lack of hypoxic selectivity, or specificity on HIF isoforms. The basic approach consists in the inhibition of different steps of the HIF activation pathway: transcription, translation, stability, transport into nucleus, heterodimerization, binding to DNA and transcriptional activity, and HIF target genes. HIF-1α inhibitors have been more extensively investigated than those of HIF-2α. Below, we briefly report the main aspects of the inhibition strategy and examples of chemical agents used. For a more detailed discussion about drugs, targets, and mechanisms, more specific reviews should be consulted [ 121 , 122 , 123 ].

Considering the whole HIF pathway from the beginning, the first target of inhibition can be transcription and translation processes. Transcription can be inhibited by different kinds of compounds, such as aminoflavone [ 124 ], GL331 [ 125 ], and anthracyclines [ 126 ]. Other compounds belonging to cardiac glycosides [ 127 ], steroids [ 128 ], topoisomerase inhibitors [ 129 ], and microtubule binding agents [ 130 ] show the inhibitory effect of translation rate of HIF mRNA by different mechanisms. However, these compounds lack specificity on isoforms. Interestingly, YC-1 shows a specificity to HIF-1, but not to HIF-2, in macrophages [ 131 ]. Inhibition of HIF-1α translation by digoxigenin increases sensitivity of pancreatic cancer cells to gemcitabine [ 132 ].

A second target for inhibition can be HIF stability. Some inhibitors weaken stability of HIF through the induction of its degradation. Panobinostat, a histone deacetylase inhibitor, disrupts the HSP90/HDAC6 complex, which normally interacts with HIF-1α to prevent its degradation, thus blocking of complex formation induces HIF-1α degradation more rapidly [ 133 ]. Similarly, another histone deacetylase inhibitor, MPT0G157, decreases HIF-1α in colorectal cancer [ 134 ]. Other HDAC inhibitors, such as Vorinostat, inhibit hypoxia machinery through downregulation of HIF-1α and VEGF. Currently, Vorinostat is used to treat cutaneous T cell lymphoma [ 135 ]. Promising results are expected from other approved HDAC inhibitors: romidepsin [ 136 ], belinostat [ 137 ], panobinostat [ 138 ], and chidamide [ 139 ]. Furthermore, rapamycin induces HIF-1 degradation and enhances downregulation of survivin, an inhibitor of apoptosis expressed in countless malignancies. Antioxidant agents, such as N-acetyl cysteine, impair HIF-α subunit [ 140 ].

A crucial step for HIF activation is the heterodimerization process. Chemical agents used in this strategy target the PAS domains of HIF-1α and HIF-2α, resulting in inhibition of heterodimerization. Interestingly, exploiting structural differences in PAS-B domain between HIF-1α and HIF-2α, compounds PT2399 and PT2385 have been found to specifically inhibit HIF-2α activity and showed anticancer properties in both cellular and animal renal carcinoma (ccRCC). Patients with ccRCC and recurrent glioblastoma treated with these inhibitors exhibited very promising results [ 141 , 142 ], thus they are under investigation in phase II clinical trials. Encouraging results are expected from the second-generation HIF-2α inhibitors, PT2977 and 0 × 3 [ 143 ]. Acriflavine, belonging to a different class of compounds, can also block binding of PAS-B domain of HIF-1α and HIF-2α to HIF-1β [ 31 ]. HIF, as a transcriptional factor, exerts it activity into the nucleus. Thus, impairment of HIF nuclear localization can be another strategy to target. Inhibition of ERK1/2 pathway by natural products (e.g., Kaempferol) and chemicals (PD98059 and U0126) affects the phosphorylation of both HIF-α proteins and triggers CRM1-dependent nuclear export of HIF-α. Consequently, transcriptional activity of HIF is hampered [ 144 , 145 ]. Other targets include the DNA binding and transcriptional activity. Chemical agents, such as echinomycin and doxorubicin, impair binding of HIF to chromatin, resulting in blocking of its transcriptional activity [ 146 , 147 ]. Alternatively, agents (e.g., chetomin) affect the ability of HIF to form complex with transcriptional coactivators CBP/p300 [ 148 ]. Inhibition of HIF transcriptional coactivators, such as CBP and p300, can also be an attractive strategy to inhibit the HIF pathway. Two domains, the histone acetyltransferase [ 149 ] and the bromodomain (BRD), are present in these coactivators. Thus, drugs addressing these domains may affect interaction of coactivator with HIF. Two BRD inhibitors of p300 are in experimental testing: CCS1477 against solid tumors and metastatic prostate cancer (phase I/IIa studies) and hematological malignancies, and CG1350 against multiple myeloma cell proliferation [ 150 ].

It should also be mentioned that some inhibitors target different steps of the HIF pathway. For example, PX-478 acts at three levels: decreases HIF-1α transcription, translation, and inhibits de-ubiquitination, favoring protein degradation [ 151 ]. Similarly, bortezomib, a proteasome inhibitor, acts as a repressor of HIF-1α transcription, translation, and blocks the recruitment of the coactivator p300 [ 152 , 153 ]. Multiple myeloma is treated with this drug [ 154 ]. The Ca 2+ channel blocker NNC 55-0396 represses HIF-1 activation, increases HIF-1α hydroxylation and degradation, and inhibits its de novo synthesis [ 155 ]. CRLX-101 represses HIF-1α stability and translation [ 156 ]. Glyceollins block HIF-1α translation and stability via different mechanisms, inhibition of the Pi3k/AKT/mTOR pathway and decreasing HSP90 binding [ 157 ].

In addition to the HIF pathway steps previously reported, other components of the HIF system that mediate the hypoxic response mechanism may be potential drug targets. For example, drugs that promote PHD activity or strengthen the interaction between PHD and HIF, and pharmacological inhibition of mitochondrial respiration.

Another strategy to achieve some of the previous interactions is the use of peptides based on the amino acids sequence of HIF-α isoforms. In fact, once introduced into the cell, a competition between peptides and endogenous HIF-α is established, resulting in inhibition of HIF activity or their association with inhibitory proteins. Knowledge of HIF-α structural domains (DNA/binding and transactivation/regulatory) is very useful to model such peptides. Transduction technology is usually used to deliver peptides inside cells. Different examples of peptides that inhibit HIF heterodimerization have been reported. Polypeptides corresponding to the bHLH, PAS, and N/TAD, or the bHLH and PAS of HIF-3α domains of different length form inactive complexes that inhibit interaction with HRE of target genes [ 158 , 159 ]. An HIF-1α-derived peptide reduces binding of endogenous HIF to the target genes, resulting in reduction of HIF-1α activity. Pancreatic cancer cells and xenograft animal models treated with this variant exhibit a reduction of glucose uptake and cell growth [ 160 ]. TAT-Ainp1 peptide, hampering the bHLH domain of ARNT, suppresses HIF-1 activity [ 161 ]. The cyclic hexapeptide-CLLFVY fused with TAT epitope shows a reduction of HIF-1α/ARNT association and decreased HIF-1 activity [ 162 ]. Other peptides have been investigated in the context of HIF-dependent transactivation. Peptides from phage display libraries and synthetic HIF-1α were investigated for their ability for binding to p300. These studies allowed to identify and develop some peptidomimetic HIF-1α/p300 inhibitors [ 163 , 164 ]. Since phosphorylation of the ERK-targeted domain (ETD) in HIF-1α by ERK1/2 is activated in human cancers [ 165 ] to allow HIF-1α accumulation into the nucleus, peptides that target this step have also been tested. After initial observation of HIF-1α inhibition by the competitor-peptide ETD, subsequent studies revealed that fusion of ETD with HIV-1 trans-activator of transcription (TAT) was able to inhibit the ERK-dependent transcriptional activity of HIF-1α (but not HIF-2α). The TAT/ETD inhibition, evident only under hypoxia, affects some cancer cell properties: metabolic adaptation, migration, and induction of apoptosis.

Finally, other approaches have also been proposed, including hypoxia-activated prodrugs (HAPs) [ 166 ]. HAPs are first enzymatically converted by one-electron reduction into a prodrug radical anion. In well-oxygenated tissues, the reduction event is reversible. Conversely, under hypoxia, the radical anion either fragments or is reduced further to an active cytotoxin that kills the hypoxic cells engaging a pharmacological target. In this way, HAPs exploit the low levels of oxygen to achieve selectivity [ 167 ]. The nitroimidazole mustard evofosfamide (TH-302) is the most advanced HAP, and it is in phase III trials for pancreatic adenocarcinoma and soft tissue sarcoma [ 168 , 169 ]. Praziqual (E09) has been recommended in bladder cancer surgery [ 170 ].

Taken together, these data show that the modulation of the HIF pathway in cancer therapy is very attractive and promising. Thus, a detailed understanding of each step of the pathway as well as the specific role of each isoform is essential to develop new and effective drugs.

6. Conclusions

Many studies have highlighted a complex metabolic reprogramming occurring in cancer cells which often face hypoxia. HIFs are transcriptional complexes acting as primary transducers of oxygen levels through oxygen-sensing PHD enzymes. In a PHD-mediated manner, HIFs control countless cellular functions, including proliferation and metabolism.

In the present review, we have highlighted the importance of the HIF-1 system in the adaption of cancer cell metabolism to hypoxia, a process that is essential to promote cancer cell survival, proliferation, and metastasis. The impact of hypoxia is particularly evident on mitochondria and mitochondrial metabolism, including changes in ROS production and signaling. In the last two decades, different studies have investigated the role of HIF-1 in the metabolic reprogramming of different pathways, including glycolysis, glycogen synthesis, lipid metabolism, ETC and TCA cycles, glutamine and serine, ROS production, as well as biogenesis and autophagy of mitochondria. The resulting interplay between HIF-1 and mitochondria is crucial to face the hypoxic condition of tumor cells: oxygen homeostasis in hypoxia is ensured since HIF-1 suppresses mitochondrial oxidative metabolism by reducing oxygen consumption.

Thus, significant developments have been made towards understanding the role of HIF-1 in cancer cells as a master regulator of cancer progression and as a potential target for cancer therapy. However, different aspects of HIF members need to be clarified. For example, the interaction of HIF-1α with other members of the family (HIF-2α and HIF-3α) in the adaption process during hypoxia, and the specific role of each member of the family. Understanding the regulatory mechanism is very important for identifying specific therapeutic targets. Strictly connected with HIF, targeting hypoxia is a potential therapy to face the progression of various cancers and allow long-term survival for patients.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

Conceptualization, V.I. (Vittoria Infantino) and V.I. (Vito Iacobazzi); writing—original draft preparation V.I. (Vito Iacobazzi), S.T., V.I. (Vittoria Infantino), P.C. and A.S.; critical revision, V.I. (Vito Iacobazzi), V.I. (Vittoria Infantino) and S.T.; funding acquisition, S.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by grants from the University of Basilicata and the University of Bari.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. McKeown S.R. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response Br. J. Radiol. 2014 87 20130676 10.1259/bjr.20130676 24588669 PMC4064601

2. Gottesman M.M. Mechanisms of cancer drug resistance Ann. Rev. Med. 2002 53 615 627 10.1146/annurev.med.53.082901.103929 11818492

3. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations J. Clin. Investig. 2013 123 3664 3671 10.1172/JCI67230 23999440 PMC3754249

4. Strickaert A. Saiselet M. Dom G. De Deken X. Dumont J.E. Feron O. Sonveaux P. Maenhaut C. Cancer heterogeneity is not compatible with one unique cancer cell metabolic map Oncogene 2017 36 2637 2642 10.1038/onc.2016.411 27797377 PMC5442421

5. Payen V.L. Porporato P.E. Baselet B. Sonveaux P. Metabolic changes associated with tumor metastasis, Part 1: Tumor pH, glycolysis and the pentose phosphate pathway Cell. Mol. Life Sci. 2016 73 1333 1348 10.1007/s00018-015-2098-5 26626411 PMC11108399

6. Fearon K.C. Glass D.J. Guttridge D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways Cell Metab. 2012 16 153 166 10.1016/j.cmet.2012.06.011 22795476

7. Petruzzelli M. Wagner E.F. Mechanisms of metabolic dysfunction in cancer-associated cachexia Genes Dev. 2016 30 489 501 10.1101/gad.276733.115 26944676 PMC4782044

8. Sun N.Y. Yang M.H. Metabolic reprogramming and epithelial-mesenchymal plasticity: Opportunities and challenges for cancer therapy Front. Oncol. 2020 10 792 10.3389/fonc.2020.00792 32509584 PMC7252305

9. Fuhrmann D.C. Brune B. Mitochondrial composition and function under the control of hypoxia Redox Biol. 2017 12 208 215 10.1016/j.redox.2017.02.012 28259101 PMC5333533

10. Fuhrmann D.C. Wittig I. Heide H. Dehne N. Brune B. Chronic hypoxia alters mitochondrial composition in human macrophages Biochim. Biophys. Acta 2013 1834 2750 2760 10.1016/j.bbapap.2013.09.023 24140568

11. Prabhakar N.R. Semenza G.L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2 Physiol. Rev. 2012 92 967 1003 10.1152/physrev.00030.2011 22811423 PMC3893888

12. Jiang B.H. Rue E. Wang G.L. Roe R. Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 J. Biol. Chem. 1996 271 17771 17778 10.1074/jbc.271.30.17771 8663540

13. Jiang B.H. Zheng J.Z. Leung S.W. Roe R. Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension J. Biol. Chem. 1997 272 19253 19260 10.1074/jbc.272.31.19253 9235919

14. Lando D. Peet D.J. Gorman J.J. Whelan D.A. Whitelaw M.L. Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor Genes Dev. 2002 16 1466 1471 10.1101/gad.991402 12080085 PMC186346

15. Wood S.M. Gleadle J.M. Pugh C.W. Hankinson O. Ratcliffe P.J. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells J. Biol. Chem. 1996 271 15117 15123 10.1074/jbc.271.25.15117 8662957

16. Wang G.L. Jiang B.H. Rue E.A. Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc. Natl. Acad. Sci. USA 1995 92 5510 5514 10.1073/pnas.92.12.5510 7539918 PMC41725

17. Huang L.E. Arany Z. Livingston D.M. Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit J. Biol. Chem. 1996 271 32253 32259 10.1074/jbc.271.50.32253 8943284

18. Iyer N.V. Leung S.W. Semenza G.L. The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation Genomics 1998 52 159 165 10.1006/geno.1998.5416 9782081

19. Ema M. Taya S. Yokotani N. Sogawa K. Matsuda Y. Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development Proc. Natl. Acad. Sci. USA 1997 94 4273 4278 10.1073/pnas.94.9.4273 9113979 PMC20712

20. Wiener C.M. Booth G. Semenza G.L. In vivo expression of mRNAs encoding hypoxia-inducible factor 1 Biochem. Biophys. Res. Commun. 1996 225 485 488 10.1006/bbrc.1996.1199 8753788

21. Wiesener M.S. Jurgensen J.S. Rosenberger C. Scholze C.K. Horstrup J.H. Warnecke C. Mandriota S. Bechmann I. Frei U.A. Pugh C.W. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs FASEB J. 2003 17 271 273 10.1096/fj.02-0445fje 12490539

22. Hu C.J. Wang L.Y. Chodosh L.A. Keith B. Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation Mol. Cell. Biol. 2003 23 9361 9374 10.1128/MCB.23.24.9361-9374.2003 14645546 PMC309606

23. Raval R.R. Lau K.W. Tran M.G. Sowter H.M. Mandriota S.J. Li J.L. Pugh C.W. Maxwell P.H. Harris A.L. Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol. Cell. Biol. 2005 25 5675 5686 10.1128/MCB.25.13.5675-5686.2005 15964822 PMC1157001

24. Gu Y.Z. Moran S.M. Hogenesch J.B. Wartman L. Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha Gene Expr. 1998 7 205 213 9840812 PMC6151950

25. Hara S. Hamada J. Kobayashi C. Kondo Y. Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: Suppression of HIF-mediated gene expression by HIF-3alpha Biochem. Biophys. Res. Commun. 2001 287 808 813 10.1006/bbrc.2001.5659 11573933

26. Maynard M.A. Qi H. Chung J. Lee E.H. Kondo Y. Hara S. Conaway R.C. Conaway J.W. Ohh M. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex J. Biol. Chem. 2003 278 11032 11040 10.1074/jbc.M208681200 12538644

27. Heidbreder M. Frohlich F. Johren O. Dendorfer A. Qadri F. Dominiak P. Hypoxia rapidly activates HIF-3alpha mRNA expression FASEB J. 2003 17 1541 1543 10.1096/fj.02-0963fje 12824304

28. Pasanen A. Heikkila M. Rautavuoma K. Hirsila M. Kivirikko K.I. Myllyharju J. Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2 Int. J. Biochem. Cell Biol. 2010 42 1189 1200 10.1016/j.biocel.2010.04.008 20416395

29. Kaelin W.G. Jr. Ratcliffe P.J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway Mol. Cell 2008 30 393 402 10.1016/j.molcel.2008.04.009 18498744

30. Pappalardi M.B. McNulty D.E. Martin J.D. Fisher K.E. Jiang Y. Burns M.C. Zhao H. Ho T. Sweitzer S. Schwartz B. Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites Biochem. J. 2011 436 363 369 10.1042/BJ20101201 21410436

31. Lee K. Zhang H. Qian D.Z. Rey S. Liu J.O. Semenza G.L. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization Proc. Natl. Acad. Sci. USA 2009 106 17910 17915 10.1073/pnas.0909353106 19805192 PMC2764905

32. Chandel N.S. McClintock D.S. Feliciano C.E. Wood T.M. Melendez J.A. Rodriguez A.M. Schumacker P.T. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing J. Biol. Chem. 2000 275 25130 25138 10.1074/jbc.M001914200 10833514

33. Goyal P. Weissmann N. Grimminger F. Hegel C. Bader L. Rose F. Fink L. Ghofrani H.A. Schermuly R.T. Schmidt H.H. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species Free Radic. Biol. Med. 2004 36 1279 1288 10.1016/j.freeradbiomed.2004.02.071 15110393

34. Nakazawa M.S. Keith B. Simon M.C. Oxygen availability and metabolic adaptations Nat. Rev. Cancer 2016 16 663 673 10.1038/nrc.2016.84 27658636 PMC5546320

35. Xie H. Simon M.C. Oxygen availability and metabolic reprogramming in cancer J. Biol. Chem. 2017 292 16825 16832 10.1074/jbc.R117.799973 28842498 PMC5641881

36. Christofk H.R. Vander Heiden M.G. Harris M.H. Ramanathan A. Gerszten R.E. Wei R. Fleming M.D. Schreiber S.L. Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 2008 452 230 233 10.1038/nature06734 18337823

37. Lee J. Kim H.K. Han Y.M. Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription Int. J. Biochem. Cell Biol. 2008 40 1043 1054 10.1016/j.biocel.2007.11.009 18191611

38. Yang W. Xia Y. Ji H. Zheng Y. Liang J. Huang W. Gao X. Aldape K. Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation Nature 2011 480 118 122 10.1038/nature10598 22056988 PMC3235705

39. Luo W. Hu H. Chang R. Zhong J. Knabel M. O’Meally R. Cole R.N. Pandey A. Semenza G.L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 2011 145 732 744 10.1016/j.cell.2011.03.054 21620138 PMC3130564

40. Gao X. Wang H. Yang J.J. Liu X. Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase Mol. Cell 2012 45 598 609 10.1016/j.molcel.2012.01.001 22306293 PMC3299833

41. Christofk H.R. Vander Heiden M.G. Wu N. Asara J.M. Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein Nature 2008 452 181 186 10.1038/nature06667 18337815

42. Chaneton B. Hillmann P. Zheng L. Martin A.C.L. Maddocks O.D.K. Chokkathukalam A. Coyle J.E. Jankevics A. Holding F.P. Vousden K.H. Serine is a natural ligand and allosteric activator of pyruvate kinase M2 Nature 2012 491 458 462 10.1038/nature11540 23064226 PMC3894725

43. Anastasiou D. Poulogiannis G. Asara J.M. Boxer M.B. Jiang J.K. Shen M. Bellinger G. Sasaki A.T. Locasale J.W. Auld D.S. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses Science 2011 334 1278 1283 10.1126/science.1211485 22052977 PMC3471535

44. Hitosugi T. Kang S. Vander Heiden M.G. Chung T.W. Elf S. Lythgoe K. Dong S. Lonial S. Wang X. Chen G.Z. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth Sci. Signal 2009 2 ra73 10.1126/scisignal.2000431 19920251 PMC2812789

45. Lv L. Li D. Zhao D. Lin R. Chu Y. Zhang H. Zha Z. Liu Y. Li Z. Xu Y. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth Mol. Cell 2011 42 719 730 10.1016/j.molcel.2011.04.025 21700219 PMC4879880

46. Vander Heiden M.G. Cantley L.C. Thompson C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation Science 2009 324 1029 1033 10.1126/science.1160809 19460998 PMC2849637

47. Semenza G.L. Regulation of metabolism by hypoxia-inducible factor 1 Cold Spring Harb. Symp. Quant. Biol. 2011 76 347 353 10.1101/sqb.2011.76.010678 21785006

48. Favaro E. Bensaad K. Chong M.G. Tennant D.A. Ferguson D.J. Snell C. Steers G. Turley H. Li J.L. Gunther U.L. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells Cell Metab. 2012 16 751 764 10.1016/j.cmet.2012.10.017 23177934

49. Lee W.N. Guo P. Lim S. Bassilian S. Lee S.T. Boren J. Cascante M. Go V.L. Boros L.G. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment Br. J. Cancer 2004 91 2094 2100 10.1038/sj.bjc.6602243 15599384 PMC2409791

50. Brizel D.M. Schroeder T. Scher R.L. Walenta S. Clough R.W. Dewhirst M.W. Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer Int. J. Radiat. Oncol. Biol. Phys. 2001 51 349 353 10.1016/S0360-3016(01)01630-3 11567808

51. Walenta S. Wetterling M. Lehrke M. Schwickert G. Sundfor K. Rofstad E.K. Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers Cancer Res. 2000 60 916 921 10706105

52. Garcia C.K. Goldstein J.L. Pathak R.K. Anderson R.G. Brown M.S. Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: Implications for the Cori cycle Cell 1994 76 865 873 10.1016/0092-8674(94)90361-1 8124722

53. Jones R.S. Morris M.E. Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease Clin. Pharmacol. Ther. 2016 100 454 463 10.1002/cpt.418 27351344 PMC5533588

54. Leite T.C. Coelho R.G. Da Silva D. Coelho W.S. Marinho-Carvalho M.M. Sola-Penna M. Lactate downregulates the glycolytic enzymes hexokinase and phosphofructokinase in diverse tissues from mice FEBS Lett. 2011 585 92 98 10.1016/j.febslet.2010.11.009 21074528

55. Lee S.H. McIntyre D. Honess D. Hulikova A. Pacheco-Torres J. Cerdan S. Swietach P. Harris A.L. Griffiths J.R. Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo Br. J. Cancer 2018 119 622 630 10.1038/s41416-018-0216-5 30206370 PMC6162214

56. De la Cruz-Lopez K.G. Castro-Munoz L.J. Reyes-Hernandez D.O. Garcia-Carranca A. Manzo-Merino J. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches Front. Oncol. 2019 9 1143 10.3389/fonc.2019.01143 31737570 PMC6839026

57. Sonveaux P. Vegran F. Schroeder T. Wergin M.C. Verrax J. Rabbani Z.N. De Saedeleer C.J. Kennedy K.M. Diepart C. Jordan B.F. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice J. Clin. Investig. 2008 118 3930 3942 10.1172/JCI36843 19033663 PMC2582933

58. Chiche J. Brahimi-Horn M.C. Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer J. Cell. Mol. Med. 2010 14 771 794 10.1111/j.1582-4934.2009.00994.x 20015196 PMC3823111

59. Faubert B. Li K.Y. Cai L. Hensley C.T. Kim J. Zacharias L.G. Yang C. Do Q.N. Doucette S. Burguete D. Lactate Metabolism in Human Lung Tumors Cell 2017 171 358 371 10.1016/j.cell.2017.09.019 28985563 PMC5684706

60. Samanta D. Semenza G.L. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors Biochim. Biophys. Acta Rev. Cancer 2018 1870 15 22 10.1016/j.bbcan.2018.07.002 30006019

61. Siska P.J. Rathmell J.C. T cell metabolic fitness in antitumor immunity Trends Immunol. 2015 36 257 264 10.1016/j.it.2015.02.007 25773310 PMC4393792

62. Todisco S. Convertini P. Iacobazzi V. Infantino V. TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma Cancers 2019 12 68 10.3390/cancers12010068 31881713 PMC7016696

63. Bensaad K. Favaro E. Lewis C.A. Peck B. Lord S. Collins J.M. Pinnick K.E. Wigfield S. Buffa F.M. Li J.L. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation Cell Rep. 2014 9 349 365 10.1016/j.celrep.2014.08.056 25263561

64. Huang D. Li T. Li X. Zhang L. Sun L. He X. Zhong X. Jia D. Song L. Semenza G.L. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression Cell Rep. 2014 8 1930 1942 10.1016/j.celrep.2014.08.028 25242319

65. Du W. Zhang L. Brett-Morris A. Aguila B. Kerner J. Hoppel C.L. Puchowicz M. Serra D. Herrero L. Rini B.I. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism Nat. Commun. 2017 8 1769 10.1038/s41467-017-01965-8 29176561 PMC5701259

66. Rohrig F. Schulze A. The multifaceted roles of fatty acid synthesis in cancer Nat. Rev. Cancer 2016 16 732 749 10.1038/nrc.2016.89 27658529

67. Chen R. Xu M. Nagati J. Garcia J.A. Coordinate regulation of stress signaling and epigenetic events by Acss2 and HIF-2 in cancer cells PLoS ONE 2017 12 e0190241 10.1371/journal.pone.0190241 29281714 PMC5744998

68. Kamphorst J.J. Cross J.R. Fan J. de Stanchina E. Mathew R. White E.P. Thompson C.B. Rabinowitz J.D. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids Proc. Natl. Acad. Sci. USA 2013 110 8882 8887 10.1073/pnas.1307237110 23671091 PMC3670379

69. Peck B. Schulze A. Lipid desaturation—the next step in targeting lipogenesis in cancer? FEBS J. 2016 283 2767 2778 10.1111/febs.13681 26881388

70. Gottgens E.L. van den Heuvel C.N. de Jong M.C. Kaanders J.H. Leenders W.P. Ansems M. Bussink J. Span P.N. ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker Cancers 2019 11 1971 10.3390/cancers11121971 31817870 PMC6966650

71. Infantino V. Iacobazzi V. Palmieri F. Menga A. ATP-citrate lyase is essential for macrophage inflammatory response Biochem. Biophys. Res. Commun. 2013 440 105 111 10.1016/j.bbrc.2013.09.037 24051091

72. Infantino V. Pierri C.L. Iacobazzi V. Metabolic routes in inflammation: The citrate pathway and its potential as therapeutic target Curr. Med. Chem. 2019 26 7104 7116 10.2174/0929867325666180510124558 29745322

73. Mylonis I. Sembongi H. Befani C. Liakos P. Siniossoglou S. Simos G. Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression J. Cell Sci. 2012 125 3485 3493 10.1242/jcs.106682 22467849 PMC3516382

74. Triantafyllou E.A. Georgatsou E. Mylonis I. Simos G. Paraskeva E. Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2018 1863 1142 1152 10.1016/j.bbalip.2018.06.015 29908837

75. Kourti M. Ikonomou G. Giakoumakis N.N. Rapsomaniki M.A. Landegren U. Siniossoglou S. Lygerou Z. Simos G. Mylonis I. CK1delta restrains lipin-1 induction, lipid droplet formation and cell proliferation under hypoxia by reducing HIF-1alpha/ARNT complex formation Cell Signal 2015 27 1129 1140 10.1016/j.cellsig.2015.02.017 25744540 PMC4390155

76. Siniossoglou S. Phospholipid metabolism and nuclear function: Roles of the lipin family of phosphatidic acid phosphatases Biochim. Biophys. Acta 2013 1831 575 581 10.1016/j.bbalip.2012.09.014 23026159

77. Qiu B. Ackerman D. Sanchez D.J. Li B. Ochocki J.D. Grazioli A. Bobrovnikova-Marjon E. Diehl J.A. Keith B. Simon M.C. HIF2alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma Cancer Discov. 2015 5 652 667 10.1158/2159-8290.CD-14-1507 25829424 PMC4456212

78. Gimm T. Wiese M. Teschemacher B. Deggerich A. Schodel J. Knaup K.X. Hackenbeck T. Hellerbrand C. Amann K. Wiesener M.S. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1 FASEB J. 2010 24 4443 4458 10.1096/fj.10-159806 20624928

79. Maier A. Wu H. Cordasic N. Oefner P. Dietel B. Thiele C. Weidemann A. Eckardt K.U. Warnecke C. Hypoxia-inducible protein 2 Hig2/Hilpda mediates neutral lipid accumulation in macrophages and contributes to atherosclerosis in apolipoprotein E-deficient mice FASEB J. 2017 31 4971 4984 10.1096/fj.201700235R 28760743

80. Zhang X. Saarinen A.M. Hitosugi T. Wang Z. Wang L. Ho T.H. Liu J. Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia eLife 2017 6 10.7554/eLife.31132 29256392 PMC5739538

81. Ackerman D. Tumanov S. Qiu B. Michalopoulou E. Spata M. Azzam A. Xie H. Simon M.C. Kamphorst J.J. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation Cell Rep. 2018 24 2596 2605.e5 10.1016/j.celrep.2018.08.015 30184495 PMC6137821

82. Ader I. Brizuela L. Bouquerel P. Malavaud B. Cuvillier O. Sphingosine kinase 1: A new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells Cancer Res. 2008 68 8635 8642 10.1158/0008-5472.CAN-08-0917 18922940

83. Morotti M. Bridges E. Valli A. Choudhry H. Sheldon H. Wigfield S. Gray N. Zois C.E. Grimm F. Jones D. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer Proc. Natl. Acad. Sci. USA 2019 116 12452 12461 10.1073/pnas.1818521116 31152137 PMC6589752

84. Sun R.C. Denko N.C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth Cell Metab. 2014 19 285 292 10.1016/j.cmet.2013.11.022 24506869 PMC3920584

85. Altman B.J. Stine Z.E. Dang C.V. From Krebs to clinic: Glutamine metabolism to cancer therapy Nat. Rev. Cancer 2016 16 619 634 10.1038/nrc.2016.71 27492215 PMC5484415

86. Wise D.R. Ward P.S. Shay J.E. Cross J.R. Gruber J.J. Sachdeva U.M. Platt J.M. DeMatteo R.G. Simon M.C. Thompson C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability Proc. Natl. Acad. Sci. USA 2011 108 19611 19616 10.1073/pnas.1117773108 22106302 PMC3241793

87. Le A. Lane A.N. Hamaker M. Bose S. Gouw A. Barbi J. Tsukamoto T. Rojas C.J. Slusher B.S. Zhang H. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells Cell Metab. 2012 15 110 121 10.1016/j.cmet.2011.12.009 22225880 PMC3345194

88. Rathmell W.K. Chen S. VHL inactivation in renal cell carcinoma: Implications for diagnosis, prognosis and treatment Expert Rev. Anticancer Ther. 2008 8 63 73 10.1586/14737140.8.1.63 18095884 PMC2873028

89. Okazaki A. Gameiro P.A. Christodoulou D. Laviollette L. Schneider M. Chaves F. Stemmer-Rachamimov A. Yazinski S.A. Lee R. Stephanopoulos G. Glutaminase and poly (ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers J. Clin. Investig. 2017 127 1631 1645 10.1172/JCI87800 28346230 PMC5409089

90. Convertini P. Todisco S. De Santis F. Pappalardo I. Iacobazzi D. Castiglione Morelli M.A. Fondufe-Mittendorf Y.N. Martelli G. Palmieri F. Infantino V. Transcriptional Regulation Factors of the Human Mitochondrial Aspartate/Glutamate Carrier Gene, Isoform 2 (SLC25A13): USF1 as Basal Factor and FOXA2 as Activator in Liver Cells Int. J. Mol. Sci. 2019 20 1888 10.3390/ijms20081888 PMC6515469 30995827

91. Harding H.P. Zhang Y. Zeng H. Novoa I. Lu P.D. Calfon M. Sadri N. Yun C. Popko B. Paules R. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress Mol. Cell 2003 11 619 633 10.1016/S1097-2765(03)00105-9 12667446

92. Donnelly R.P. Finlay D.K. Glucose, glycolysis and lymphocyte responses Mol. Immunol. 2015 68 513 519 10.1016/j.molimm.2015.07.034 26260211

93. DeNicola G.M. Chen P.H. Mullarky E. Sudderth J.A. Hu Z. Wu D. Tang H. Xie Y. Asara J.M. Huffman K.E. NRF2 regulates serine biosynthesis in non-small cell lung cancer Nat. Genet. 2015 47 1475 1481 10.1038/ng.3421 26482881 PMC4721512

94. Jia X.Q. Zhang S. Zhu H.J. Wang W. Zhu J.H. Wang X.D. Qiang J.F. Increased expression of PHGDH and prognostic significance in colorectal cancer Transl. Oncol. 2016 9 191 196 10.1016/j.tranon.2016.03.006 27267836 PMC4907894

95. Jing Z. Heng W. Aiping D. Yafei Q. Shulan Z. Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2013 23 1465 1469 10.1097/IGC.0b013e3182a0c068 24247658

96. Samanta D. Park Y. Andrabi S.A. Shelton L.M. Gilkes D.M. Semenza G.L. PHGDH expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis Cancer Res. 2016 76 4430 4442 10.1158/0008-5472.CAN-16-0530 27280394

97. Iacobazzi V. Infantino V. Castegna A. Andria G. Hyperhomocysteinemia: Related genetic diseases and congenital defects, abnormal DNA methylation and newborn screening issues Mol. Genet. Metab. 2014 113 27 33 10.1016/j.ymgme.2014.07.016 25087163

98. Iacobazzi V. Castegna A. Infantino V. Andria G. Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool Mol. Genet. Metab. 2013 110 25 34 10.1016/j.ymgme.2013.07.012 23920043

99. Fan J. Ye J. Kamphorst J.J. Shlomi T. Thompson C.B. Rabinowitz J.D. Quantitative flux analysis reveals folate-dependent NADPH production Nature 2014 510 298 302 10.1038/nature13236 24805240 PMC4104482

100. Ye J. Fan J. Venneti S. Wan Y.W. Pawel B.R. Zhang J. Finley L.W. Lu C. Lindsten T. Cross J.R. Serine catabolism regulates mitochondrial redox control during hypoxia Cancer Discov. 2014 4 1406 1417 10.1158/2159-8290.CD-14-0250 25186948 PMC4258153

101. Garcia-Bermudez J. Baudrier L. La K. Zhu X.G. Fidelin J. Sviderskiy V.O. Papagiannakopoulos T. Molina H. Snuderl M. Lewis C.A. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours Nat. Cell Biol. 2018 20 775 781 10.1038/s41556-018-0118-z 29941933 PMC6030478

102. Infantino V. Dituri F. Convertini P. Santarsiero A. Palmieri F. Todisco S. Mancarella S. Giannelli G. Iacobazzi V. Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma Biochim. Biophys. Acta Mol. Basis Dis. 2019 1865 38 47 10.1016/j.bbadis.2018.10.018 30321589

103. King A. Selak M.A. Gottlieb E. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer Oncogene 2006 25 4675 4682 10.1038/sj.onc.1209594 16892081

104. Morin A. Letouze E. Gimenez-Roqueplo A.P. Favier J. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy Int. J. Cancer 2014 135 2237 2248 10.1002/ijc.29080 25124653

105. Vatrinet R. Leone G. De Luise M. Girolimetti G. Vidone M. Gasparre G. Porcelli A.M. The alpha-ketoglutarate dehydrogenase complex in cancer metabolic plasticity Cancer Metab. 2017 5 3 10.1186/s40170-017-0165-0 28184304 PMC5289018

106. Hayashi T. Asano Y. Shintani Y. Aoyama H. Kioka H. Tsukamoto O. Hikita M. Shinzawa-Itoh K. Takafuji K. Higo S. Higd1a is a positive regulator of cytochrome c oxidase Proc. Natl. Acad. Sci. USA 2015 112 1553 1558 10.1073/pnas.1419767112 25605899 PMC4321285

107. Tello D. Balsa E. Acosta-Iborra B. Fuertes-Yebra E. Elorza A. Ordonez A. Corral-Escariz M. Soro I. Lopez-Bernardo E. Perales-Clemente E. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting Complex I activity Cell Metab. 2011 14 768 779 10.1016/j.cmet.2011.10.008 22100406

108. Lai R.K. Xu I.M. Chiu D.K. Tse A.P. Wei L.L. Law C.T. Lee D. Wong C.M. Wong M.P. Ng I.O. NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016 22 3105 3117 10.1158/1078-0432.CCR-15-1987 26819450

109. Chan S.Y. Zhang Y.Y. Hemann C. Mahoney C.E. Zweier J.L. Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2 Cell Metab. 2009 10 273 284 10.1016/j.cmet.2009.08.015 19808020 PMC2759401

110. Favaro E. Ramachandran A. McCormick R. Gee H. Blancher C. Crosby M. Devlin C. Blick C. Buffa F. Li J.L. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU PLoS ONE 2010 5 e10345 10.1371/journal.pone.0010345 20436681 PMC2859946

111. Babot M. Birch A. Labarbuta P. Galkin A. Characterisation of the active/de-active transition of mitochondrial complex I Biochim. Biophys. Acta 2014 1837 1083 1092 10.1016/j.bbabio.2014.02.018 24569053 PMC4331042

112. Ciano M. Fuszard M. Heide H. Botting C.H. Galkin A. Conformation-specific crosslinking of mitochondrial complex I FEBS Lett. 2013 587 867 872 10.1016/j.febslet.2013.02.039 23454639

113. Puissegur M.P. Mazure N.M. Bertero T. Pradelli L. Grosso S. Robbe-Sermesant K. Maurin T. Lebrigand K. Cardinaud B. Hofman V. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity Cell Death Differ. 2011 18 465 478 10.1038/cdd.2010.119 20885442 PMC3131992

114. Balsa E. Marco R. Perales-Clemente E. Szklarczyk R. Calvo E. Landazuri M.O. Enriquez J.A. NDUFA4 is a subunit of complex IV of the mammalian electron transport chain Cell Metab. 2012 16 378 386 10.1016/j.cmet.2012.07.015 22902835

115. Chen Z. Li Y. Zhang H. Huang P. Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression Oncogene 2010 29 4362 4368 10.1038/onc.2010.193 20498629

116. Kurtulus S. Tripathi P. Opferman J.T. Hildeman D.A. Contracting the ’mus cells’—does down-sizing suit us for diving into the memory pool? Immunol. Rev. 2010 236 54 67 10.1111/j.1600-065X.2010.00920.x 20636808 PMC2907539

117. Bellot G. Garcia-Medina R. Gounon P. Chiche J. Roux D. Pouyssegur J. Mazure N.M. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains Mol. Cell. Biol. 2009 29 2570 2581 10.1128/MCB.00166-09 19273585 PMC2682037

118. Zhang H. Bosch-Marce M. Shimoda L.A. Tan Y.S. Baek J.H. Wesley J.B. Gonzalez F.J. Semenza G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia J. Biol. Chem. 2008 283 10892 10903 10.1074/jbc.M800102200 18281291 PMC2447655

119. Drogat B. Bouchecareilh M. North S. Petibois C. Deleris G. Chevet E. Bikfalvi A. Moenner M. Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells J. Cell. Physiol. 2007 212 463 472 10.1002/jcp.21044 17348020

120. Li P. Zhang D. Shen L. Dong K. Wu M. Ou Z. Shi D. Redox homeostasis protects mitochondria through accelerating ROS conversion to enhance hypoxia resistance in cancer cells Sci. Rep. 2016 6 22831 10.1038/srep22831 26956544 PMC4783784

121. Albadari N. Deng S. Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy Expert Opin. Drug. Discov. 2019 14 667 682 10.1080/17460441.2019.1613370 31070059 PMC6559821

122. Mylonis I. Chachami G. Simos G. Specific inhibition of HIF activity: Can peptides lead the way? Cancers 2021 13 410 10.3390/cancers13030410 33499237 PMC7865418

123. Schonberger T. Fandrey J. Prost-Fingerle K. Ways into Understanding HIF Inhibition Cancers 2021 13 159 10.3390/cancers13010159 33466454 PMC7796500

124. Terzuoli E. Puppo M. Rapisarda A. Uranchimeg B. Cao L. Burger A.M. Ziche M. Melillo G. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion Cancer Res. 2010 70 6837 6848 10.1158/0008-5472.CAN-10-1075 20736373 PMC2932848

125. Chang H. Shyu K.G. Lee C.C. Tsai S.C. Wang B.W. Hsien Lee Y. Lin S. GL331 inhibits HIF-1alpha expression in a lung cancer model Biochem. Biophys. Res. Commun. 2003 302 95 100 10.1016/S0006-291X(03)00111-6 12593853

126. Pang Y. Yang C. Schovanek J. Wang H. Bullova P. Caisova V. Gupta G. Wolf K.I. Semenza G.L. Zhuang Z. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway Oncotarget 2017 8 22313 22324 10.18632/oncotarget.16224 28423608 PMC5410225

127. Zhang H. Qian D.Z. Tan Y.S. Lee K. Gao P. Ren Y.R. Rey S. Hammers H. Chang D. Pili R. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth Proc. Natl. Acad. Sci. USA 2008 105 19579 19586 10.1073/pnas.0809763105 19020076 PMC2604945

128. Gkotinakou I.M. Kechagia E. Pazaitou-Panayiotou K. Mylonis I. Liakos P. Tsakalof A. Calcitriol Suppresses HIF-1 and HIF-2 Transcriptional activity by reducing HIF-1/2alpha protein levels via a VDR-independent mechanism Cells 2020 9 11 10.3390/cells9112440 PMC7695316 33182300

129. Rapisarda A. Zalek J. Hollingshead M. Braunschweig T. Uranchimeg B. Bonomi C.A. Borgel S.D. Carter J.P. Hewitt S.M. Shoemaker R.H. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts Cancer Res. 2004 64 6845 6848 10.1158/0008-5472.CAN-04-2116 15466170

130. Thomas S.L. Zhong D. Zhou W. Malik S. Liotta D. Snyder J.P. Hamel E. Giannakakou P. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1 Cell Cycle 2008 7 2409 2417 10.4161/cc.6410 18682687 PMC2573855

131. Strowitzki M.J. Ritter A.S. Kimmer G. Schneider M. Hypoxia-adaptive pathways: A pharmacological target in fibrotic disease? Pharmacol. Res. 2019 147 104364 10.1016/j.phrs.2019.104364 31376431

132. Xiong G. Stewart R.L. Chen J. Gao T. Scott T.L. Samayoa L.M. O’Connor K. Lane A.N. Xu R. Collagen prolyl 4-hydroxylase 1 is essential for HIF-1alpha stabilization and TNBC chemoresistance Nat. Commun. 2018 9 4456 10.1038/s41467-018-06893-9 30367042 PMC6203834

133. Kovacs J.J. Murphy P.J. Gaillard S. Zhao X. Wu J.T. Nicchitta C.V. Yoshida M. Toft D.O. Pratt W.B. Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol. Cell 2005 18 601 607 10.1016/j.molcel.2005.04.021 15916966

134. Huang Y.C. Huang F.I. Mehndiratta S. Lai S.C. Liou J.P. Yang C.R. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis Oncotarget 2015 6 18590 18601 10.18632/oncotarget.4068 26087180 PMC4621912

135. Mann B.S. Johnson J.R. He K. Sridhara R. Abraham S. Booth B.P. Verbois L. Morse D.E. Jee J.M. Pope S. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007 13 2318 2322 10.1158/1078-0432.CCR-06-2672 17438089

136. Prince H.M. Dickinson M. Romidepsin for cutaneous T-cell lymphoma Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012 18 3509 3515 10.1158/1078-0432.CCR-11-3144 22535155

137. Poole R.M. Belinostat: First global approval Drugs 2014 74 1543 1554 10.1007/s40265-014-0275-8 25134672

138. Cheng T. Grasse L. Shah J. Chandra J. Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma Drugs Today 2015 51 491 504 10.1358/dot.2015.51.8.2362311 26380387

139. Ning Z.Q. Li Z.B. Newman M.J. Shan S. Wang X.H. Pan D.S. Zhang J. Dong M. Du X. Lu X.P. Chidamide (CS055/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Cancer Chemother. Pharmacol. 2012 69 901 909 10.1007/s00280-011-1766-x 22080169

140. Gao P. Zhang H. Dinavahi R. Li F. Xiang Y. Raman V. Bhujwalla Z.M. Felsher D.W. Cheng L. Pevsner J. HIF-dependent antitumorigenic effect of antioxidants in vivo Cancer Cell 2007 12 230 238 10.1016/j.ccr.2007.08.004 17785204 PMC2084208

141. Chen W. Hill H. Christie A. Kim M.S. Holloman E. Pavia-Jimenez A. Homayoun F. Ma Y. Patel N. Yell P. Targeting renal cell carcinoma with a HIF-2 antagonist Nature 2016 539 112 117 10.1038/nature19796 27595394 PMC5340502

142. Cho H. Du X. Rizzi J.P. Liberzon E. Chakraborty A.A. Gao W. Carvo I. Signoretti S. Bruick R.K. Josey J.A. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models Nature 2016 539 107 111 10.1038/nature19795 27595393 PMC5499381

143. Scheuermann T.H. Li Q. Ma H.W. Key J. Zhang L. Chen R. Garcia J.A. Naidoo J. Longgood J. Frantz D.E. Allosteric inhibition of hypoxia inducible factor-2 with small molecules Nat. Chem. Biol. 2013 9 271 276 10.1038/nchembio.1185 23434853 PMC3604136

144. Mylonis I. Chachami G. Samiotaki M. Panayotou G. Paraskeva E. Kalousi A. Georgatsou E. Bonanou S. Simos G. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha J. Biol. Chem. 2006 281 33095 33106 10.1074/jbc.M605058200 16954218

145. Mylonis I. Kourti M. Samiotaki M. Panayotou G. Simos G. Mortalin-mediated and ERK-controlled targeting of HIF-1alpha to mitochondria confers resistance to apoptosis under hypoxia J. Cell Sci. 2017 130 466 479 27909249 10.1242/jcs.195339

146. Kong D. Park E.J. Stephen A.G. Calvani M. Cardellina J.H. Monks A. Fisher R.J. Shoemaker R.H. Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity Cancer Res. 2005 65 9047 9055 10.1158/0008-5472.CAN-05-1235 16204079

147. Lee K. Qian D.Z. Rey S. Wei H. Liu J.O. Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells Proc. Natl. Acad. Sci. USA 2009 106 2353 2358 10.1073/pnas.0812801106 19168635 PMC2650160

148. Kung A.L. Zabludoff S.D. France D.S. Freedman S.J. Tanner E.A. Vieira A. Cornell-Kennon S. Lee J. Wang B. Wang J. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Cancer Cell 2004 6 33 43 10.1016/j.ccr.2004.06.009 15261140

149. Lyberopoulou A. Venieris E. Mylonis I. Chachami G. Pappas I. Simos G. Bonanou S. Georgatsou E. MgcRacGAP interacts with HIF-1alpha and regulates its transcriptional activity Cell Physiol. Biochem. 2007 20 995 1006 10.1159/000110460 17982282

150. Imayoshi N. Yoshioka M. Chauhan J. Nakata S. Toda Y. Fletcher S. Strovel J.W. Takata K. Ashihara E. CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model Biochem. Biophys. Res. Commun. 2017 484 262 268 10.1016/j.bbrc.2017.01.088 28115161

151. Koh M.Y. Spivak-Kroizman T. Venturini S. Welsh S. Williams R.R. Kirkpatrick D.L. Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha Mol. Cancer Ther. 2008 7 90 100 10.1158/1535-7163.MCT-07-0463 18202012

152. Befani C.D. Vlachostergios P.J. Hatzidaki E. Patrikidou A. Bonanou S. Simos G. Papandreou C.N. Liakos P. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells J. Mol. Med. 2012 90 45 54 10.1007/s00109-011-0805-8 21909688

153. Hideshima T. Mitsiades C. Akiyama M. Hayashi T. Chauhan D. Richardson P. Schlossman R. Podar K. Munshi N.C. Mitsiades N. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 2003 101 1530 1534 10.1182/blood-2002-08-2543 12393500

154. Kane R.C. Bross P.F. Farrell A.T. Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 2003 8 508 513 10.1634/theoncologist.8-6-508 14657528

155. Kim K.H. Kim D. Park J.Y. Jung H.J. Cho Y.H. Kim H.K. Han J. Choi K.Y. Kwon H.J. NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1alpha signal transduction J. Mol. Med. 2015 93 499 509 10.1007/s00109-014-1235-1 25471482

156. Pham E. Birrer M.J. Eliasof S. Garmey E.G. Lazarus D. Lee C.R. Man S. Matulonis U.A. Peters C.G. Xu P. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015 21 808 818 10.1158/1078-0432.CCR-14-2810 25524310

157. Lee S.H. Jee J.G. Bae J.S. Liu K.H. Lee Y.M. A group of novel HIF-1alpha inhibitors, glyceollins, blocks HIF-1alpha synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding J. Cell. Physiol. 2015 230 853 862 10.1002/jcp.24813 25204544

158. Makino Y. Cao R. Svensson K. Bertilsson G. Asman M. Tanaka H. Cao Y. Berkenstam A. Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression Nature 2001 414 550 554 10.1038/35107085 11734856

159. Yamashita T. Ohneda O. Nagano M. Iemitsu M. Makino Y. Tanaka H. Miyauchi T. Goto K. Ohneda K. Fujii-Kuriyama Y. Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS Mol. Cell. Biol. 2008 28 1285 1297 10.1128/MCB.01332-07 18070924 PMC2258751

160. Chen J. Zhao S. Nakada K. Kuge Y. Tamaki N. Okada F. Wang J. Shindo M. Higashino F. Takeda K. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism Am. J. Pathol. 2003 162 1283 1291 10.1016/S0002-9440(10)63924-7 12651620 PMC1851236

161. Wang Y. Thompson J.D. Chan W.K. A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocator Chem. Biol. Interact. 2013 203 401 411 10.1016/j.cbi.2013.02.003 23454269 PMC3661001

162. Miranda E. Nordgren I.K. Male A.L. Lawrence C.E. Hoakwie F. Cuda F. Court W. Fox K.R. Townsend P.A. Packham G.K. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells J. Am. Chem. Soc. 2013 135 10418 10425 10.1021/ja402993u 23796364 PMC3715890

163. Hetherington K. Hegedus Z. Edwards T.A. Sessions R.B. Nelson A. Wilson A.J. Stapled peptides as HIF-1alpha/p300 inhibitors: Helicity enhancement in the bound state increases inhibitory potency Chemistry 2020 26 7638 7646 10.1002/chem.202000417 32307728 PMC7318359

164. Kyle H.F. Wickson K.F. Stott J. Burslem G.M. Breeze A.L. Tiede C. Tomlinson D.C. Warriner S.L. Nelson A. Wilson A.J. Exploration of the HIF-1alpha/p300 interface using peptide and Adhiron phage display technologies Mol. Biosyst. 2015 11 2738 2749 10.1039/C5MB00284B 26135796

165. Lavoie H. Gagnon J. Therrien M. ERK signalling: A master regulator of cell behaviour, life and fate Nat. Rev. Mol. Cell Biol. 2020 21 607 632 10.1038/s41580-020-0255-7 32576977

166. Wilson W.R. Hay M.P. Targeting hypoxia in cancer therapy Nat. Rev. Cancer 2011 11 393 410 10.1038/nrc3064 21606941

167. Wardman P. Dennis M.F. Everett S.A. Patel K.B. Stratford M.R. Tracy M. Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: The kinetic basis for hypoxia-selective, bioreductive drugs Biochem. Soc. Symp. 1995 61 171 194 8660394 10.1042/bss0610171

168. Borad M.J. Reddy S.G. Bahary N. Uronis H.E. Sigal D. Cohn A.L. Schelman W.R. Stephenson J. Jr. Chiorean E.G. Rosen P.J. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015 33 1475 1481 10.1200/JCO.2014.55.7504 PMC4881365 25512461

169. Chawla S.P. Cranmer L.D. Van Tine B.A. Reed D.R. Okuno S.H. Butrynski J.E. Adkins D.R. Hendifar A.E. Kroll S. Ganjoo K.N. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014 32 3299 3306 10.1200/JCO.2013.54.3660 PMC4588714 25185097

170. Shukla S.K. Purohit V. Mehla K. Gunda V. Chaika N.V. Vernucci E. King R.J. Abrego J. Goode G.D. Dasgupta A. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer Cancer Cell 2017 32 71 87.e7 10.1016/j.ccell.2017.06.004 28697344 PMC5533091